The stock has since climbed to $29.02, representing a 5.4% gain on his recent purchase. According to InvestingPro data, GLSI is trading near its 52-week high of $30.82 and appears overvalued based on ...
Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,400 shares of the company on 12-31-2024. This trade was reported by Quiver Quantitative using data from a ...
Greenwich Lifesciences (NASDAQ:GLSI) stock is heading higher on Tuesday after the U.S. Food and Drug Administration (FDA) lifted a hold on a Phase III clinical trial. That hold from the FDA was ...
Hosted on MSN
Why did GLSI stock rise pre-market today?
・CEO Snehal Patel said the FDA has already reviewed plans to expand the trial to include all patient types, with over 1,300 patients enrolled. ・Data presented at the AACR Annual Meeting 2026 showed a ...
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move. The stock action follows a corporate update earlier this week ...
Greenwich LifeSciences (NASDAQ:GLSI) is simply skyrocketing today, up more than 60% on heavy trading volume. It turns out that a big advancement for the cancer-fighting company is behind the move. So ...
Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01. Discover the top trade setups and strategies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results